Kenneth Galbraith, Zymeworks CEO
Updated: Zymeworks wanted a Big Pharma partner for its bispecific. Jazz Pharmaceuticals said OK
Speaking in a Starbucks booth on the sidelines of ASCO in June, Kenneth Galbraith emphasized he wanted what Daiichi Sankyo got for its HER2 breakout …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.